跳至主要内容
临床试验/NCT05136235
NCT05136235Unknown不适用

Pulmonary Hypertension in Extremely Preterm Infants - A Prospective Cohort Study

Universitair Ziekenhuis Brussel0 个研究点目标入组 350 人开始时间: 2022年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
350
主要终点
Presence of pulmonary hypertension

研究概览

简要总结

Extremely preterm infants are at risk for developing bronchopulmonary dysplasia (BPD) and associated chronic pulmonary hypertension (PH), a consequence of altered pulmonary vasculature. This condition occurs in about 25% of babies with BPD, and the association grows with increasing BPD severity. Other risk factors have been described as well. Morbidity and mortality associated with prematurity and/or BPD increase significantly in the presence of PH.

Thus, international guidelines encourage the use of standardized screening protocols for this condition. However, several questions regarding these recommendations are left unanswered, such as a clear definition for PH in this population.

The research aim is to prospectively evaluate prevalence, risk factors and clinical course of PH in these children. The investigators aim to identify at-risk infants early on and ultimately improve survival making use of an early targeted intervention.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
— 至 2 Weeks(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Preterm infants with
  • •Gestational age <28 0/7 weeks
  • •Birth weight <1000 grams

排除标准

  • •Major congenital malformations
  • •Structural airway or lung disease
  • •Congenital heart disease
  • •Lack of parental consent

研究组 & 干预措施

Extremely preterm newborns

Other

All extremely preterm newborns in Flanders will be included, it is a single arm study

干预措施: Echocardiography (Diagnostic Test)

Extremely preterm newborns

Other

All extremely preterm newborns in Flanders will be included, it is a single arm study

干预措施: NT-proBNP (Diagnostic Test)

结局指标

主要结局

Presence of pulmonary hypertension

时间窗: at 12 months of age

Pulmonary hypertension will be defined as one or more of the following echocardiographic findings: * Presence of a cardiac shunt with bidirectional or right-to-left flow * Estimated right ventricular systolic pressure (RVSP) \>40 mmHg * RVSP/systemic systolic blood pressure (SBP) ratio \>0.5 * Presence of ventricular septal wall flattening

Presence of pulmonary hypertension

时间窗: 3-10 days of life (time depending on the timing of the first echocardiography)

Pulmonary hypertension will be defined as one or more of the following echocardiographic findings: * Presence of a cardiac shunt with bidirectional or right-to-left flow * Estimated right ventricular systolic pressure (RVSP) \>40 mmHg * RVSP/systemic systolic blood pressure (SBP) ratio \>0.5 * Presence of ventricular septal wall flattening

Presence of pulmonary hypertension

时间窗: at 28 days of life

Pulmonary hypertension will be defined as one or more of the following echocardiographic findings: * Presence of a cardiac shunt with bidirectional or right-to-left flow * Estimated right ventricular systolic pressure (RVSP) \>40 mmHg * RVSP/systemic systolic blood pressure (SBP) ratio \>0.5 * Presence of ventricular septal wall flattening

Presence of pulmonary hypertension

时间窗: at 36 weeks PMA

Pulmonary hypertension will be defined as one or more of the following echocardiographic findings: * Presence of a cardiac shunt with bidirectional or right-to-left flow * Estimated right ventricular systolic pressure (RVSP) \>40 mmHg * RVSP/systemic systolic blood pressure (SBP) ratio \>0.5 * Presence of ventricular septal wall flattening

Presence of pulmonary hypertension

时间窗: at 6 months of age

Pulmonary hypertension will be defined as one or more of the following echocardiographic findings: * Presence of a cardiac shunt with bidirectional or right-to-left flow * Estimated right ventricular systolic pressure (RVSP) \>40 mmHg * RVSP/systemic systolic blood pressure (SBP) ratio \>0.5 * Presence of ventricular septal wall flattening

次要结局

  • Birth weight(at birth)
  • ROP(at 36 weeks)
  • NEC(at 36 weeks)
  • VAP(at 36 weeks)
  • Presence of bronchopulmonary dysplasia(at 36 weeks PMA)
  • Gestational age(at birth)
  • Small for gestational age(at birth)
  • Oligohydramnios(at birth)
  • Maternal hypertensive disorders(at birth)
  • PDA(at 36 weeks)
  • Sepsis(up to discharge from the NICU, an average of 16 weeks)
  • Presence of bronchopulmonary dysplasia(at 28 days of life)

研究者

申办方类型
Other
责任方
Sponsor

相似试验